Stage IV Bladder Cancer Clinical Trial
Official title:
A Phase I Trial of Intravesical Ad-p53 Treatment in Locally Advanced and Metastatic Bladder Cancer
Phase I trial to study the effectiveness of gene therapy in treating patients with advanced bladder cancer. Inserting the p53 gene into a person's bladder cancer cells may improve the body's ability to fight cancer
PRIMARY OBJECTIVES:
I. Determine the safety and toxicity of adenovirus p53 (Ad-p53) gene therapy in patients
with locally advanced or metastatic bladder cancer.
II. Measure infection with Ad-p53 and confirm expression of p53 after infection.
III. Characterize clinical response of measurable tumor in these patients. IV. Determine the
duration of effect of this treatment in these patients. V. Define the time course of
elimination of vector from urinary bladder.
OUTLINE: This is a dose escalation study.
Group 1 patients receive adenovirus p53 (Ad-p53) intravesically on days 1 and 4. Treatment
continues every 4 weeks for a maximum of 6 courses in the absence of disease progression or
unacceptable toxicity.
Cohorts of 3 patients in group 1 receive escalating doses of Ad-p53. In the absence of grade
3 or worse toxicity in the first 3 patients treated, subsequent cohorts of 3 patients each
receive escalating doses of Ad-p53 on the same schedule. If 1 of 3 patients experiences
grade 3 toxicity, an additional 3 patients are treated at that dose level and dose
escalation continues. If 1 of 3 patients experience grade 4 toxicity or 2 of 3 patients
experience grade 3 toxicity, dose escalation ceases and the MTD is defined as the previous
dose level. Group 2 patients receive Ad-p53 at the MTD on days 1-4, and group 3 patients
receive Ad-p53 at the MTD on days 1-4 and 8-11.
Patients are followed on day 28, then every 3 months for 1 year or until disease
progression.
PROJECTED ACCRUAL: A maximum of 24 patients will be accrued for this study (3-12 patients
for group 1; 3-6 patients for group 2; and 6 patients for group 3).
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02122172 -
Afatinib in Advanced Refractory Urothelial Cancer
|
Phase 2 | |
| Completed |
NCT03229278 -
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
|
Phase 1 | |
| Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
| Completed |
NCT01938573 -
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT00112905 -
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
|
Phase 2 | |
| Terminated |
NCT00072137 -
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
|
Phase 1 | |
| Completed |
NCT00072150 -
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT00028756 -
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
|
Phase 3 | |
| Completed |
NCT00407485 -
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
|
Phase 2 | |
| Terminated |
NCT00003452 -
Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder
|
Phase 2 | |
| Completed |
NCT00005831 -
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer
|
Phase 2 | |
| Completed |
NCT00021099 -
Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
|
Phase 2 | |
| Terminated |
NCT01382706 -
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
|
Phase 2 | |
| Active, not recruiting |
NCT04267575 -
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
|
N/A | |
| Terminated |
NCT01954173 -
Adjuvant Radiation for High Risk Bladder Cancer
|
N/A | |
| Terminated |
NCT00004856 -
Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium
|
Phase 2 | |
| Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
| Terminated |
NCT01282333 -
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT01828736 -
Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma
|
Phase 2 | |
| Terminated |
NCT02316548 -
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
|
Phase 2 |